Axio is a premier provider of biostatistics and data management services to pharmaceutical, biotechnology, and medical device companies.
We are focused exclusively on delivering timely, high-quality data and thoughtful analysis to help our clients develop, execute, evaluate, and document clinical studies confidently and efficiently.
Our company was founded in 1979 by an internationally recognized group of biostatisticians and epidemiologists from the University of Washington, many of whom remain closely involved with the company. Their vision was to create a flexible, responsive organization to facilitate their clinical trials and research.
Axio today reflects that pedigree—a world-class team of management and PhD/MS statisticians and programmers and a recognized leader in biostatistics-related clinical trial support services.
Our industry-leading Data Monitoring Committee services, deep biostatistics expertise, operational flexibility, and experience across diverse therapeutic areas are the basis of the value we bring to large pharmaceutical and small biotechnology companies alike.
The depth of expertise and experience of our professional staff is reflected in the results we have achieved for our clients, encompassing:
Today and ongoing, Axio’s chief commitment is to our clients’ success, and to continually improving our systems and services to help our clients optimize productivity and mitigate risk in the clinical trials process.
Interpreting the complex data sets generated by advanced genomic technologies—particularly next-generation sequencing—is intrinsically statistical. Axio offers a comprehensive range of statistical genetics and genomics research services to pharmaceutical and biotechnology companies, diagnostic companies, and academic and government laboratories focused on drug discovery and development, drug repositioning, and companion diagnostics development.
Using a unique interdisciplinary approach that merges deep experience in statistical genetics, bioinformatics, and biostatistics with clinical understanding, our highly trained PhD/MS staff apply state-of-the-art statistical genetics and computational methods to support researchers focused on experimental design, analysis, and interpretation of high-throughput genomic data.
Axio’s Statistical Genetics and Genomics services include:
Axio provides a full range of statistical analysis and programming capabilities spanning preclinical through Phase 4 clinical development.
Our highly trained PhD/MS biostatisticians collaborate with our clients on optimal design, implementation, evaluation, and reporting on all phases of the clinical development program.
Our specialists can also provide statistical guidance and representation at FDA meetings and FDA advisory meetings.
Our services spanning preclinical through Phase 4 clinical trials include:
Axio’s clinical data management team delivers solutions that address all aspects of the clinical trial process—from protocol development though report writing—with uncompromising accuracy and adherence to the highest data management standards.
Our work pivots on industry-recognized and FDA-compliant data management systems that enable us to deliver high-quality output with confidence.
Our team applies extensive data management experience spanning preclinical through Phase 4 development as well as a broad range of therapeutic areas, using both paper and EDC systems.
To facilitate decision-making, we customize data metrics and study management reports to client needs.
Axio’s Integrated Data Management Solutions include:
Axio Research, LLC has not received any reviews.
Axio Research, LLC has not received any endorsements.